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Objectives: Bipolar disorder imposes high economic burden, with direct costs 
estimated at $30.7 billion. Lurasidone is an atypical antipsychotic approved for the 
treatment of depressive episodes associated with bipolar I disorder. The objective of 
this study was to compare the cost-effectiveness of lurasidone and quetiapine XR in 
patients with bipolar depression. MethOds: A cost-effectiveness model was devel-
oped to compare lurasidone to quetiapine XR over a 3-month time horizon from a 
US payer perspective. Effectiveness inputs were based on indirect comparison of 
the proportion of patients achieving remission (MADRS total score ≤ 12 by week 6-8), 
obtained from lurasidone and quetiapine XR pivotal trials versus placebo. Resource 
utilization (emergency room visits, hospitalizations, and office visits) were obtained 
from an expert panel study. Drug costs were estimated using mean dose from clini-
cal trials and wholesale acquisition costs. Costs of resources were obtained from 
a retrospective database study of bipolar depression patients. Model results were 
tested using deterministic and probabilistic sensitivity analyses. Results: Over the 
3-month time horizon of the model, 52.0% of lurasidone patients achieved remission 
versus 43.2% of quetiapine XR patients. Mean emergency room visits, inpatient days, 
and office visits were lower for lurasidone patients (0.48, 2.1, 9.3) than quetiapine XR 
patients (0.50, 2.2, 9.6), respectively. Total costs were lower for lurasidone patients 
($4,447) than quetiapine XR patients ($4,546). Cost-effectiveness results showed 
that lurasidone was dominant over quetiapine XR. Model testing showed that the 
results were robust to changes in other parameters. One-way sensitivity analysis 
showed that the model may be sensitive to the drug cost/month, remission rate, or 
hospital cost/day. Probabilistic sensitivity analyses showed lurasidone has a 97.4% 
probability of being cost-effective compared to quetiapine XR at a willingness-to-pay 
threshold of $5,000 per remission. cOnclusiOns: Based on this model, lurasidone 
is cost-effective compared to quetiapine XR in patients with bipolar depression.
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Objectives: Generalized Anxiety Disorder (GAD) affects around 6.8 million U.S. 
adults. It places a considerable economic burden upon patients and payers alike. 
Selective serotonin reuptake inhibitors (SSRIs) are among the first-line therapy for 
treating GAD. Currently, Escitalopram and Paroxetine are the only SSRIs approved 
by U.S. FDA for treating GAD. To assess, from a third party payer’s perspective, the 
cost-effectiveness of Escitalopram and Paroxetine in the treatment of GAD in the 
U.S. MethOds: A decision analytic model with a 12 month time horizon, adapted 
to the U.S. setting was constructed. Outcome measured as a reduction in Hamilton 
Anxiety Scale (HAMA) scores, and adverse event probabilities were obtained from a 
head-to-head randomized trial. Resource utilization and associated costs were esti-
mated from standard national sources. Analyses from a third party payer’s perspec-
tive focused on the direct medical cost of treatment e.g. drugs, physician visits and 
dispensing cost. Annual cost per person for the treatment was calculated and the cost-
effectiveness of the treatment options was measured. All costs were reported in 2013 
US Dollars. Cost-effectiveness was expressed as the incremental cost-effectiveness 
ratio (ICER). Sensitivity analysis on key input parameters and Monte Carlo simula-
tion was performed to measure the robustness of the model. Results: Escitalopram 
dominated Paroxetine by having both, lower total annual cost ($4587 vs. $5243, respec-
tively) and better outcomes (14 HAMA vs. 13 HAMA point reduction, respectively).The 
ICER was found to be -$656/HAMA point which indicates improved effectiveness along 
with reduction in costs by adopting Escitalopram over Paroxetine. Sensitivity analysis 
demonstrated the robustness of the model. cOnclusiOns: Escitalopram appears 
to be cost-effective compared with Paroxetine in treatment of GAD in the U.S. from 
a third party payer’s perspective.
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Objectives: The objectives of this study are: (1) to estimate the expected health 
outcomes of atypical antipsychotics (AAPs) and other non-stimulant attention-def-
icit/hyperactivity disorder (ADHD) medications based on trade-offs between clinical 
effectiveness and adverse effects and (2) to evaluate the cost-effectiveness of AAPs 
compared to other non-stimulant ADHD medications. Both aims target children 
and adolescents with ADHD who have failed prior stimulant therapy. MethOds: 
We used decision analysis to compare three alternatives for treating children and 
adolescents with ADHD who failed initial stimulant treatment: (1) AAPs (2) a selec-
tive norepinephrine reuptake inhibitor (atomoxetine), and (3) selective a2-adrenergic 
agonists (clonidine and guanfacine). Probability estimates and quality adjusted life 
year (QALY) weights were derived from a literature review. One-way deterministic 
sensitivity analyses were performed to evaluate the robustness of the results. Cost-
effectiveness was estimated using the expected health outcomes derived from the 
decision analysis and expected costs from the literature. A Monte Carlo simulation 
was performed as a probabilistic sensitivity analysis. Results: After one year of 
ADHD pharmacotherapy, clonidine/guanfacine provided the highest expected QALY 
(0.95) followed by atomoxetine (expected QALY 0.94). Atypical antipsychotics yielded 
the lowest health outcome with an expected QALY of 0.84. In the cost-effectiveness 
analysis, the AAP strategy was dominated as it was less effective and more costly 
ance claims database (TruvenHealth MarketScan® Medicaid) from January 2007 
to June 2012. Patients with at least two treatment episodes in the first year after 
the initial filled prescription were identified. The end of a treatment episode was 
defined as a period of 60 days with no filled BUP/NAL prescriptions following 
the theoretical end of the last filled prescription. An ordered logistic regression 
model was used to analyze the impact of initial treatment episode duration on the 
number of new episodes in the year following the end of the first episode. Health 
care resource utilization and related costs during the first year after initiation 
were compared between the two groups. Results: 2,223 patients were included 
in the analysis. During the first year, 86% of patients had only one treatment 
episode, 13% had two and 1% had three. Compared to patients treated continu-
ously over 12 months, the multiple treatment episode groups had lower medica-
tion costs (-$2,877) but higher psychiatric inpatient costs (+$720), non-psychiatric 
inpatient costs (+$2001) and emergency room costs over 12 months. Total health 
care costs over 12 months were higher among multiple treatment episode patients 
($16,583 vs. $15.123, p= 0.0004). cOnclusiOns: Despite lower medication costs, 
total health care costs over 12 months were higher among patients with multiple 
treatment episodes compared to patients treated continuously.
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Objectives: Preliminary data from a multicenter, open-label mirror study of 
patients with schizophrenia aged 18–65 years (Kane et al. J Med Econ. 2013;16:917) 
demonstrated that switching from oral standard of care (SOC) antipsychotics 
to aripiprazole once-monthly (AOM) reduced total psychiatric hospitalization 
rates from 41.5% in the SOC 6-month retrospective period to 14.2% in the AOM 
6-month prospective period (p< 0.0001). A subgroup of patients with at least 1 
psychiatric hospitalization while receiving oral SOC in the retrospective period 
was analyzed to estimate health care cost savings associated with AOM treatment 
initiation. MethOds: An economic model was developed to examine the impact 
on costs and outcomes of switching to AOM. Cost for hospitalizations, hospi-
tal length of stay, and cost of drug therapy were estimated for a subgroup of 76 
patients with schizophrenia who entered the ongoing mirror study (NCT01432444) 
and had at least 1 psychiatric hospitalization during the retrospective period. 
Cost estimates were obtained from HealthCare Costs and Utilization Project, pub-
lished literature, and US Bureau of Labor Statistics. Adjustments were made to 
estimate additional resource use for patients who discontinued the study (lost to 
follow-up, adverse events, met protocol/investigator withdrawal criteria, protocol 
deviation, lack of efficacy) and thus did not have complete data on resource use 
from the trial. Results: Among the 76 patients with hospitalizations during the 
retrospective period, hospitalizations were reduced to 22.4% (17/76, p< 0.0001) in 
the prospective AOM period. Total cost during the prospective period ($23,313) 
after switching to AOM was lower than that in the retrospective period ($36,415) 
by $13,102 per patient. Hospitalizations per patient were reduced from 1.16 to 
0.53. Increased cost due to AOM initiation ($6,010) was offset by reduced cost 
for hospitalizations (–$19,112). cOnclusiOns: Among patients with previous 
psychiatric hospitalizations, treatment with AOM may reduce total cost of care 
for health plans.
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Objectives: Management of patients with chronic relapsing schizophrenia is dif-
ficult and costly. We assessed the cost-effectiveness of paliperidone palmitate long-
acting injectable (PP-LAI) versus risperidone depot (RIS-LAI), olanzapine pamoate 
(OLZ-LAI), oral olanzapine (oral-OLZ) and oral clozapine (CLOZ) from the viewpoint 
of the Finnish National Health Service. MethOds: We expanded and adapted a 
1-year decision tree model that had been previously validated for Finland, with 
assistance from an expert panel. Patients started in a stable state and were treated 
as per standard procedures in Finland. Drug doses, success and relapse rates were 
determined from published clinical studies. Patient management was guided by 
expert opinion. Health state utilities were derived from the literature. Only direct 
costs were considered, including hospitalization and other institutional care, medi-
cal and nursing care, and drugs. Prices were obtained from standard lists. Outcomes 
included quality-adjusted life-years (QALYs), rates of rehospitalization and days 
with stable disease. The primary economic outcome was the incremental cost/QALY. 
One-way sensitivity analyses were performed on all pertinent costs and clinical 
inputs. Results between drugs were tested in a pairwise fashion with 10,000 Monte 
Carlo simulations each, using standard distributions for all variables. Results: 
Expected costs were € 10,691 for PP-LAI, € 12,462 for RIS-LAI, € 12,496 for OLZ-LAI, 
€ 27,270 for oral-OLZ and € 23,258 for CLOZ. QALYs were 0.829, 0.813, 0.821, 0.739 
and 0.523, respectively. Rehospitalizations were 0.25, 0.30, 0.29, 0.61, and 1.88, 
respectively and days with stable disease were 329.3, 326.2, 325.1, 283.9 and 215.6, 
respectively. In the base-case, PP-LAI dominated all other drug choices. One-way 
sensitivity analyses indicated that results were insensitive to drug costs but sensi-
tive to plausible changes in rates of adherence or hospitalization. In probability 
sensitivity analyses, results were robust overall with ICERs significantly favouring 
PP-LAI (P< 0.001). cOnclusiOns: PP-LAI was cost-effective in Finland for chronic 
relapsing schizophrenia.
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Patients entered the model according to three different adhesion states related 
to each treatment drug - fully compliant, partially compliant and non-compliant 
– and could subsequently transition between different health states during each 
monthly cycle. Probability of relapse, level of adherence, treatment discontinuation 
and adverse events associated with each intervention were sourced from literature 
and while resource use was obtained from specialist’s opinion. Costs and outcomes 
were evaluated over a 5-year horizon, and discounted at 5.0%. Exchange rate (1 
USD = 2.30 BRL) Results were presented as incremental costs/relapses avoided. 
Deterministic and probabilistic sensitivity analyses were performed Results: Total 
costs (USD): PP (15,917), OP (13,670), QP (16,845) and ZP (13,273). Hospitalization 
relapses costs (USD): PP (3,114), OP (4,504), QP (6,305) and ZP (6,459). Relapses rate: PP 
(1.15), OP (1.67), QP (2.37) and ZP (2.41). Incremental cost per relapses avoided (USD/
relapses avoided): PP vs. OP (2,247), PP vs. QP (-927), PP vs. ZP (2,644). cOnclusiOns: 
Compared with the drugs under analysis, PP demonstrates savings in terms of 
hospitalization costs. Additionally, PP is a cost-saving strategy compared to QP and 
when compared to OP and ZP, is a cost-effective therapy for the treatment of schizo-
phrenia in adults patients in Brazil.
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Objectives: Effective therapy with different drug formulations exists for Attention 
Deficit Hyperactivity Disorder (ADHD), yet poor adherence leads to suboptimal 
long-term effects for children and adolescents with ADHD. This study analyzes 
the cost-effectiveness of medication formulation (long-acting [LA] versus short-
acting [SA]) for ADHD treatments in children and adolescents taking into account 
medication adherence. MethOds: We constructed a hybrid decision tree-Markov 
model employing a third-party payer’s perspective. Evaluation included methyl-
phenidate (MPH) and atomoxetine (ATX) with long- and short-acting formulations, 
which resulted in three medication groups for comparison: LA-ATX, LA-MPH, and 
SA-MPH. Only medication costs for ADHD treatments are considered, which were 
retrieved from Consumer Reports Best Buy DrugsTM report. Quality-adjusted life expec-
tancy (QALE) was measured in quality-adjusted life-years (QALYs) considering side 
effects among medication groups. The 5-year discounted incremental costs (in 
2013 US dollars) per QALY (ICER) were reported comparing the three medication 
groups. Sensitivity analyses were performed to test the impact of uncertain model 
parameters on results. Results: Considering medication adherence, the ICERs are 
$18,926/QALY for LA-ATX ($3,417, 4.33 QALYs), $11,335/QALY for LA-MPH ($1,288, 4.26 
QALYs), and $7,816/QALY for SA-MPH ($591, 4.23 QALYs), respectively, compared 
to no treatment. LA medications are consistently cost-effectiveness compared to 
SA medications. In general, the ICERs were insensitive to variation in key param-
eters. cOnclusiOns: LA-ATX, LA-MPH, and SA-MPH are cost-effective alternatives 
for children and adolescents with ADHD when considering medication adherence. 
Treatment with long-acting medications, especially ATX, is associated with better 
health outcomes and higher medication adherence. Given there is little difference 
in health outcomes among the therapies; however, additional research on optimal 
ADHD treatments (pharmacological, behavioral, or combined therapies) is needed.
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bAckgROund/Objectives: Risperidone is a commonly used antipsychotic for 
the treatment of schizophrenia. Its major metabolic pathway is through the liver 
enzyme CYP2D6. Variants of CYP2D6 confer differing activity levels. Poor metabo-
lizer phenotype is suspected to increase the risk of adverse drug reactions that 
could lead to risperidone discontinuation and poor patient outcomes. The objective 
of this study was to assess the potential costs and outcomes of a pharmacogenetic-
guided risperidone treatment strategy for use in schizophrenics. MethOds: A 
decision analytic model was developed to estimate the incremental cost per QALY 
gained (ICER) and cost per relapse and hospitalization avoided, associated with 
a pharmacogenetic-guided strategy compared to a standard treatment approach 
for a hypothetical schizophrenic patient initiated on risperidone. We used a one-
year time horizon and a payer perspective. Model probabilities, costs, and utilities 
were obtained from the literature. One-way sensitivity analyses were performed 
to explore the possible range of results. Results: For one patient entering the 
model, pharmacogenetic-guided treatment increased QALYs (0.00047), and pre-
vented relapses (0.00782) as well as relapse-associated hospitalizations (0.00235) 
at an increased total cost ($167). This resulted in an ICER of $356,356, and costs 
of $21,468 per relapse avoided and $71,561 per hospitalization avoided relative to 
standard treatment. Findings were robust to one-way sensitivity analyses and did 
not change the base case Conclusions. cOnclusiOns: Our results suggest a phar-
macogenetic-guided treatment approach for risperidone may confer a small reduc-
tion in relapses and consequent hospitalizations, and a very minimal increase in 
QALYs for relatively low additional cost compared to standard treatment. However, 
the large ICER suggests this approach is not cost effective.
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than the other two strategies. Compared to clonidine/guanfacine, AAPs provided a 
lower QALY (0.11 QALY lost) at an additional cost of $2,186 on average. Compared to 
atomoxetine, AAPs resulted in 0.10 QALY lost at an additional cost of $2,186. These 
results were robust in sensitivity analyses. cOnclusiOns: In this decision analysis 
model, AAPs provide lower expected health outcomes than other ADHD medications 
(atomoxetine, clonidine, or guanfacine) in children and adolescents who failed prior 
stimulant therapy. Furthermore, AAPs were not a cost-effective option.
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Objectives: Staying in structured drug treatment for more than 12 weeks is 
a strong predictor of positive outcomes. Higher doses of buprenorphine and 
buprenorphine-naloxone appear to be more effective for retaining clients in treat-
ment, though the incremental cost per retained client associated with each dose is 
unknown. This study estimated cost-effectiveness thresholds for prescribing higher 
doses of buprenorphine/buprenorphine-naloxone to retain individuals in treatment 
for at least 12 weeks. MethOds: Dose, treatment duration, and retention data 
were extracted or computed from 14 randomised, controlled, double-blind clinical, 
12-26 week trials of buprenorphine/buprenorphine-naloxone maintenance treat-
ment of opioid-dependent individuals (N = 1,897). Treatment costs included drug 
preparations and supervised consumption of doses. Retention in treatment was 
used as the primary measure of clinical effectiveness. Results: Weighted mean 
treatment retention rates were 49% (2 to 7.9-mg/day), 53% (8 to 15.9-mg/day), 60% 
(16 to 23.9-mg/day) and 58% (24 to 32-mg/day). Controlling for differences in treat-
ment duration, patients dosed with 16 to 23.9-mg/day, 24 to 32-mg/day, and 8 to 
15.9-mg/day were 47% (p = 0.001), 37% (p = 0.275), and 8% (p = 0.498) more likely to 
stay in treatment for 12-26 weeks compared to patients dosed with 2 to 7.9-mg/day. 
Compared to 8 to 15.9-mg/day, a 16 to 23.9-mg/day dose was estimated to yield an 
additional 65 retentions per 1000 patients treated at an additional cost of £74,968 
(incremental cost per retention = £1,158). cOnclusiOns: If UK decision makers’ 
willingness-to-pay to retain one patient in treatment for at least 12 weeks is greater 
than £1,158, then buprenorphine/buprenorphine-naloxone prescribed at a dose of 
16 to 23.9-mg/day may cost-effectively increase the treatment retention rate.
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Objectives: The risks of smoking during pregnancy are numerous to both mother 
and fetus. While the negative effects of smoking during pregnancy can be long-
term, medical costs that are most easily linked to smoking during pregnancy occur 
shortly following birth. For example, smoking during pregnancy often results in 
prolonged hospitalization and admission of the infant to a neonatal intensive care 
unit (NICU), at a cost of thousands of dollars daily. We set out to perform the first 
health economic analysis of incentive-based treatments in a smoking, pregnant 
population. MethOds: The design of the present study was based on analysis of 
recent prospective studies examining the use of contingency management (CM) for 
the treatment of smoking during pregnancy. The resultant pooled analysis totaled 
166 women (82 contingent, 78 non-contingent) for whom clinical outcomes and 
direct hospital costs were reported. Pregnant women who reported smoking upon 
entering prenatal care were recruited from Fletcher Allen Health Care obstetric 
practices and Women, Infants, and Children (WIC) offices in and around Burlington, 
Vermont. Women were randomized between two conditions: contingent or noncon-
tingent vouchers. Those in the contingent condition received vouchers exchange-
able for retail goods contingent upon cotinine-negative urine analysis. Women in the 
non-contingent condition received vouchers independent of their smoking status. 
Vouchers were provided throughout pregnancy and for the first 3 months postpar-
tum. Results: As compared with non-contingent care, CM led to a nearly 3-fold 
reduction in admissions to the neonatal intensive care unit (NICU). Only 7.0% of 
CM women delivered infants admitted to the NICU (median charge = $9,210) versus 
19.2% among non-contingent women (median charge = $11,363). The findings from 
this study suggest that these cash-like incentives targeting at-risk patients are 
not only cost-effective but also cost-saving in pregnant smokers. cOnclusiOns: 
Incentive-based treatment towards smoking abstinence dominated usual care with 
both better outcomes and lower economic costs.
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Objectives: Schizophrenia is a chronic disorder that requires long-term treatment 
with antipsychotic medication to minimize relapse and provide benefit to patients. 
Due to the long duration of treatment, adherence is an important factor in order to 
avoid relapses and re-hospitalization. Long-acting Injectable (LAI) formulations of 
atypical antipsychotics provide constant medication delivery and thus a potential 
improve in adherence. The aim of this analysis is to assess the cost-effectiveness of 
paliperidone palmitate (PP) relative to olanzapine (OP), quetiapine (QP) and ziprazi-
done (ZP) under the Brazilian Private Healthcare System perspective. MethOds: A 
decision-analytic Markov model was developed adopting a monthly cycle length. 
